Advanced Melanoma: Resistance Mechanisms to Current Therapies.

Journal Article (Journal Article;Review)

Novel therapeutic agents introduced over the past decade, including immune checkpoint inhibitors and targeted therapies, have revolutionized the management of metastatic melanoma and significantly improved patient outcomes. Although robust and durable responses have been noted in some cases, treatment is often limited by innate or acquired resistance to these agents. This article provides an overview of known and suspected mechanisms involved with acquired resistance to BRAF/MEK inhibitors as well as developing insights into innate and acquired resistance to checkpoint inhibitors in patients with melanoma.

Full Text

Duke Authors

Cited Authors

  • Haugh, AM; Salama, AKS; Johnson, DB

Published Date

  • February 2021

Published In

Volume / Issue

  • 35 / 1

Start / End Page

  • 111 - 128

PubMed ID

  • 33759769

Pubmed Central ID

  • PMC7991196

Electronic International Standard Serial Number (EISSN)

  • 1558-1977

Digital Object Identifier (DOI)

  • 10.1016/j.hoc.2020.09.005


  • eng

Conference Location

  • United States